Subsequent consolidation therapy resulted in progressively declining fusion transcript levels, suggesting that while the TBL1XR1-RARB-positive leukemia retained some responsiveness to ATRA/ATO, this sensitivity was markedly diminished compared to classical APL. The gene discussed is RARB; the disease is acute promyelocytic leukemia.